"Leaving nothing behind": Is the bioresorbable vascular scaffold a new hope for patients with coronary artery disease?

Postepy w Kardiologii Interwencyjnej

Volumn 10, Issue 4, 2014, Pages 283-288

  Lesiak, Maciej ^a   Araszkiewicz, Aleksander ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Bioresorbable vascular scaffold; Coronary angioplasty

Indexed keywords

CLOPIDOGREL; EVEROLIMUS; GLYCERYL TRINITRATE; NITRATE; TICAGRELOR;

ACUTE CORONARY SYNDROME; ANGIOGRAPHY; ARTICLE; BIORESORBABLE SCAFFOLD; BIORESORBABLE VASCULAR SCAFFOLD; CARDIOVASCULAR DISEASE; CLINICAL STUDY; CORONARY ARTERY CIRCUMFLEX BRANCH; CORONARY ARTERY DISEASE; DEVICE SAFETY; DRUG DELIVERY SYSTEM; DRUG ELUTING STENT; HEART DEATH; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; IN-STENT RESTENOSIS; INTRAVASCULAR ULTRASOUND; INVASIVE PROCEDURE; LEFT ANTERIOR DESCENDING CORONARY ARTERY; METAL STENT; NEOINTIMA; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; OPTICAL COHERENCE TOMOGRAPHY; PERCUTANEOUS CORONARY INTERVENTION; PROTOCOL COMPLIANCE; RADIOFREQUENCY; REGISTER; REVASCULARIZATION; RISK REDUCTION; ROTATIONAL ATHERECTOMY; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; SUDDEN DEATH; SURVIVAL TIME; THROMBOSIS;

EID: 84911436758     PISSN: 17349338     EISSN: 18974295     Source Type: Journal    
DOI: 10.5114/pwki.2014.46940     Document Type: Article

References (18)

1. Lüscher TF, Steffel J, Eberli FR et al. Drug-eluting stent and coronary thrombosis. Biological mechanisms and clinical implications. Circulation 2007; 115: 1051-8.
2. Nakazawa G, Otsuka F, Nakano M, et al. The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents. J Am Coll Cardiol 2011; 57: 1314-22.
3. Otsuka F, Pacheco E, Perkins LE, et al. Long-term safety of an everolimus-eluting bioresorbable vascular scaffold and the cobalt-chromium XIENCE V stent in a porcine coronary artery model. Circ Cardiovasc Interv 2014; 7: 330-42.
4. Serruys PW, Garcia-Garcia HM, Onuma Y. From metallic cages to transient bioresorbable scaffolds: change in paradigm of coronary revascularization in the upcoming decade? Eur Heart J 2012; 33: 16-25.
5. Ormiston JA, Serruys PW, Regar E, et al. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet 2008; 371: 899-907.
6. Serruys PW, Ormiston JA, Onuma Y, et al. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet 2009; 373: 897-910.
7. Onuma Y, Dudek D, Thuesen L, et al. Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial. JACC Cardiovasc Interv 2013; 6: 999-1009.
8. Okamura T, Garg G, Gutierres-Chico JL, et al. In vivo evaluation of stent strut distribution patterns in the bioabsorbable everolimus-eluting device: an OCT ad hoc analysis of the revision 1.0 and revision 1.1 stent design in the ABSORB clinical trial. EuroIntervention 2010; 5: 932-8.
9. Diletti R, Farooq V, Girasis C, et al. Clinical and intravascular imaging outcomes at 1 and 2 years after implantation of absorb everolimus eluting bioresorbable vascular scaffolds in small vessels. Late lumen enlargement: does bioresorption matter with small vessel size? Insight from the ABSORB cohort B trial. Heart 2013; 99: 98-105.
10. Serruys PW, Onuma Y, Garcia-Garcia HM, et al. Dynamics of vessel wall changes following the implantation of the Absorb everolimus-eluting bioresorbable vascular scaffold: a multi- imaging modality study at 6, 12, 24 and 36 months. EuroIntervention 2014; 9: 1271-84.
11. Ishibashi Y, Onuma Y, Muramatsu T, et al. ABSORB EXTEND Investigators. Lessons learned from acute and late scaffold failures in the ABSORB EXTEND trial. EuroIntervention 2014; 10: 449-57.
12. Abizaid A, Costa JR Jr, Bartorelli AL, et al. The ABSORB EXTEND study: preliminary report of the twelve-month clinical outcomes in the first 512 patients enrolled. EuroIntervention 2014; pii: 20130827-06. [Epub ahead of print].
13. Serruys PW, Chevalier B, Dudek D, et al. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial. Lancet 2014 pii: S0140-6736(14)61455-0. doi: 10.1016/S0140-6736(14)61455-0. [Epub ahead of print].
14. Capodanno D1, Gori T, Nef H, et al. Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry. EuroIntervention 2014 pii: 20140707-06. doi: 10.4244/EIJY14M07-11. [Epub ahead of print].
15. Diletti R, Karanasos A, Muramatsu T, et al. Everolimus-eluting bioresorbable vascular scaffolds for treatment of patients presenting with ST- segment elevation myocardial infarction: BVS STEMI first study. Eur Heart J 2014; 35: 777-86.
16. Kocka V, Maly M, Tousek P, et al. Bioresorbable vascular scaffolds in acute ST-segment elevation myocardial infarction: a prospective multicentre study 'Prague 19'. Eur Heart J 2014; 35: 787-94.
17. Lesiak M. BVS in bifurcations - techniques, acute and long-term outcomes. Xth meeting of European Bifurcation Club, Bordeaux, 17-18 October 2014.
18. Kolandaivelu K, Swaminathan R, Gibson WJ, et al. Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings. Circulation 2011; 123: 1400-9.